| Market Capitalization (Millions $) |
9 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
66 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-9 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Biocardia Inc
Biocardia Inc. is a medical technology company that specializes in the development and commercialization of innovative therapies for cardiovascular diseases. The company focuses on regenerative medicine to address the limitations of current treatment options for heart failure, myocardial infarction, and chronic ischemic coronary artery disease.
Biocardia Inc. has developed a proprietary biotherapeutic delivery system called Helix Biotherapeutic Delivery System. It enables targeted delivery of biotherapeutic agents to the heart muscle, promoting tissue regeneration and healing. The system uses a catheter-based delivery method to precisely deliver the biotherapeutic agents to the desired location in the heart.
The company's main product, CardiAMP Cell Therapy, utilizes the Helix system to deliver a patient's own bone marrow-derived cells to the damaged heart tissue. This therapy aims to improve heart function, reduce symptoms, and enhance the quality of life for patients with heart failure. Biocardia Inc. is engaged in clinical trials to further evaluate the safety and efficacy of this therapy.
In addition to CardiAMP Cell Therapy, Biocardia Inc. is also developing other novel therapeutics and solutions for cardiovascular diseases. The company's mission is to provide innovative and effective treatments to improve patient outcomes in the field of cardiology.
Company Address: 320 Soquel Way Sunnyvale 94085 CA
Company Phone Number: 226-0120 Stock Exchange / Ticker: NASDAQ BCDA
|
13.89%